Please ensure Javascript is enabled for purposes of website accessibility

Biogen Has Growth in all the Wrong Places

By Brian Orelli, PhD – Updated Apr 5, 2017 at 7:28PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The company needs more Tysabri patients.

Biogen Idec (NASDAQ:BIIB) saw substantial growth in the third quarter, but apparently it’s coming from all the wrong places. Getting a taste of Intuitive Surgical's (NASDAQ:ISRG) medicine, investors sent the Stock Advisor pick down more than 7% even though it beat analyst revenue and earnings projections.

Revenue was up 38% year over year. Sales of Biogen’s biggest seller, multiple sclerosis drug Avonex, were up 26%, and its share of revenue from Rituxun, which it sells with Genentech (NYSE:DNA), was up 27%.

So what was the problem? Well, revenue from multiple sclerosis drug Tysabri, which Biogen sells with Elan (NYSE:ELN), was up just 172% year over year. Actually, it was the growth in the number of patients on Tysabri that disappointed.

As fellow Fool Brian Lawler pointed out last quarter, the growth of patients coming onto Tysabri had already been slowing, but a report last summer of two new cases of a rare and often deadly brain disorder seems to have smacked down the growth of paying customers to just 11.5% quarter over quarter. Granted, that's still tremendous annualized growth, but it's not going to get Elan and Biogen to their goal of 100,000 patients on Tysabri by the end of 2010.

There’s some real risk that Tysabri won't be able to compete with other multiple sclerosis drugs -- like Teva Pharmaceuticals' (NASDAQ:TEVA) Copaxone, or Rebif from EMD Serono and Pfizer (NYSE:PFE) -- on a first-line setting. Nonetheless, there's no doubt that Tysabri works. After failing other treatments, patients will likely determine that the risk/reward benefit for Tysabri is good enough to start using it, and sales will eventually pick up again.

With Biogen trading at less than 13 times its expected adjusted 2008 earnings, the company is a real steal if it can continue to produce adjusted bottom-line growth in excess of 25%. While there's some risk of a slowdown, just like the risk/reward ratio for Tysabri, there seems to be a lot more reward potential than risk built into Biogen's stock price.

Biogen is an active Stock Advisor pick. Let Fool co-founders David and Tom Gardner show you the rest of their top stock picks absolutely free with a 30-day trial.

Fool contributor Brian Orelli, Ph.D., doesn't own shares of any company mentioned in this article. Pfizer is a pick of the Income Investor and Inside Value newsletters. Intuitive Surgical is a Rule Breakers selection. The Fool owns shares of Pfizer. The Fool's disclosure policy cuts your risk.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Biogen Inc. Stock Quote
Biogen Inc.
BIIB
$276.61 (39.85%) $78.82
Pfizer Inc. Stock Quote
Pfizer Inc.
PFE
$44.43 (0.77%) $0.34
Intuitive Surgical, Inc. Stock Quote
Intuitive Surgical, Inc.
ISRG
$192.40 (3.23%) $6.02
Teva Pharmaceutical Industries Limited Stock Quote
Teva Pharmaceutical Industries Limited
TEVA
$7.96 (2.84%) $0.22
Elan Corporation Limited Stock Quote
Elan Corporation Limited
ELN

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
327%
 
S&P 500 Returns
105%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/29/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.